iShares Biotechnology ETF
U.S. stock index ETF · tracks NYSE Biotechnology Index
As of its 2026 Q2 report, iShares Biotechnology ETF held 252 positions with $9.09B in net assets. Its ten largest holdings made up 54.3% of the fund. The IBB share class costs 0.44% a year. Over the 12 months to May 2026, IBB returned 41.9%, with dividends reinvested. In 2026 Q2 it added 2 new positions and exited 8.
The iShares Biotechnology ETF (the Fund ) seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.
The fund tracks the NYSE Biotechnology Index using representative sampling, holding a portfolio of U.S.-listed biotechnology and biotech-tools companies that collectively mirrors the index's characteristics; it invests at least 80% of assets in index components and may use derivatives and cash for up to 20%. Because the fund samples rather than holds all index securities, its returns may diverge from the index.
What you own
| Company | Weight | Value | Shares | Reported price |
|---|---|---|---|---|
BlackRock Funds III | 11.66% | $1.06B | — | — |
8.08% | $734.32M | 1.5M | $496.73 | |
AMGNAmgen, Inc. | 7.83% | $711.36M | 2.0M | $362.12 |
6.84% | $621.79M | 4.9M | $126.34 | |
4.91% | $445.87M | 715.1K | $623.54 | |
ARGXArgenx SE | 3.76% | $341.58M | 368.2K | $927.77 |
3.12% | $283.62M | 942.2K | $301.03 | |
NTRANatera, Inc. | 2.89% | $262.68M | 967.7K | $271.45 |
2.78% | $252.66M | 1.3M | $187.28 | |
BIIBBiogen, Inc. | 2.47% | $224.09M | 1.0M | $216.06 |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
The 200 largest of 252 holdings, with the share counts as filed, open with a free account.
What the fund is made of
Percentages are of fund net assets. Rounding, liabilities and short positions can make totals differ from 100%.
| Stocks | 99.88% |
| Cash & short-term | 12.04% |
| Other | 0.01% |
| Derivatives | 0.00% |
These positions come to 111.92% of the fund's net assets. This counts only what the fund reported holding — the holdings disclosure covers assets, not liabilities such as borrowings — so it is not expected to reconcile to 100%.
Derivatives are shown at market value, not notional exposure.
By sector
- Health Care
- 80.7%
- Cash
- 10.8%
- International
- 8.5%
- Industrials
- 0.1%
- 1 other sector
- 0.0%
- Health Care
- 80.7%
- Cash
- 10.8%
- International
- 8.5%
- Industrials
- 0.1%
- Other
- 0.0%
How it has done
IBB share class · total returns with dividends reinvested
Volatility over the last 12 months: 14.29%. Past returns are a record, not a forecast.
Jun 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Fees & fund details
iShares Biotechnology ETF is a U.S. equity index ETF that tracks the NYSE Biotechnology Index.
- Asset class
- Equity
- Region
- United States
- Management
- Index (passive)
- Fund type
- ETF
- Features
- Non-diversified
- Expense ratio, by class
- 0.44%· IBB 0.44%
- Portfolio turnover
- 18.00% a year · as of 2025 Q3
Turnover is how much of the portfolio was replaced in a year.
Classified from what the fund holds, not from its name · 2026 Q2. The summary is a paraphrase of the prospectus; the objective is verbatim.
What changed this quarter
Positions that entered or left the fund since its previous filing. Positions that were only resized are not listed.
2 new
8 exited
Understand how this fund fits with the rest.
Explore shared holdings, compare funds and follow their businesses with your connected AI:
- “Where do my funds overlap — IBB, QQQ and the fund in my 401(k)?”
- “How do this fund’s ten biggest holdings stack up against each other?”
- “For my target-date fund, what’s the real stock-and-bond mix once you look through it?”